VIBATIV® Mechanism of Action

GlaxoSmithKline (gsk) commissioned XVIVO to create a mechanism of action animation for VIBATIV® (televancin), used in the treatment of hospital-acquired MRSA. VIBATIV® works by inhibiting cell wall synthesis, severely restricting cellular replication.


VIBATIV® Mechanism of Action



Both the quality of the final product and my experience working with XVIVO has reinforced my interest in a long-term collaboration with this team.

Alain Viel PhD, Senior Lecturer and Director of Undergraduate Research in Molecular and Cellular Biology, Harvard University